LEWIS-HALL FREDA C enters HELUS PHARMA INC. with 100K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 10/26/2026ACC: 0000912282-26-001390
100K
Baseline shares
100% direct
100K
Direct ownership
1 position
50K
Derivative underlying
2 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Shares
DirectShares owned100K
Total
100K direct100K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 100K | Direct |
| Total | 100K | 100K direct |
Derivative Holdings2
Options ("Right to Buy")
IndirectUnderlying security
Common Shares
Underlying shares
25K
Shares owned
N/A
Exercise price
5.99
Expiration
—
Exercise window
—
Restricted Share Units
DirectUnderlying security
Common Shares
Underlying shares
25K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Total
Underlying
50K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Options ("Right to Buy") Indirect | Common Shares | 5.99 | — | — | 25K | N/A |
| Restricted Share Units Direct | Common Shares | — | — | 25K | N/A | |
| Total | 50K | 0.00 | ||||